Hims Earnings Q2 2026: Revenue Growth, Guidance, and What Investors Should Know

Q2 2026 Revenue and Top-Line Performance

Hims & Hers reported quarterly revenue of [Q2_2026_REVENUE] for the three months ending June 30, 2026, compared to analyst consensus estimates of [CONSENSUS_REVENUE] (per analyst consensus from Bloomberg). This result represents a year-over-year growth rate of [YOY_REVENUE_GROWTH] compared to the same quarter in 2025.

The company's revenue engine has historically been driven by its subscription-based model across key verticals including sexual health, dermatology, mental health, and weight management. In recent quarters, the weight management category — particularly GLP-1 related offerings — has been a notable contributor to top-line momentum.

It's worth noting that Hims has been diversifying its revenue streams beyond its original men's health focus. The Hers platform, targeting women's health needs, has seen accelerating adoption, and management has pointed to new product categories as incremental growth drivers. Investors should monitor the revenue mix shift across categories, as concentration risk in any single vertical could introduce volatility to future results.

Subscriber Growth and Retention Metrics

One of the most closely watched metrics for Hims & Hers is its subscriber count, which serves as the foundation of its recurring revenue model. As of Q2 2026, the company reported [TOTAL_SUBSCRIBERS] total subscribers on its platform, compared to [PRIOR_QUARTER_SUBSCRIBERS] at the end of Q1 2026 and [PRIOR_YEAR_SUBSCRIBERS] in Q2 2025.

Sequential subscriber growth came in at [QOQ_SUB_GROWTH], while year-over-year subscriber growth was [YOY_SUB_GROWTH]. The company has consistently emphasized that subscriber lifetime value (LTV) and retention rates are improving as the platform matures and cross-selling opportunities expand.

Average Revenue Per Subscriber

Beyond raw subscriber numbers, average revenue per subscriber (ARPS) is a key indicator of the company's ability to monetize its user base. For Q2 2026, ARPS came in at [ARPS_FIGURE], reflecting [ARPS_TREND] compared to the prior year. Growth in ARPS typically signals successful upselling into higher-value treatment plans or premium personalized offerings, both of which Hims has been investing in heavily.

The interplay between subscriber growth and ARPS is critical — investors should be wary of subscriber growth that comes at the expense of per-user economics, as this could indicate unsustainable promotional spending or a shift toward lower-value customers. For more on evaluating subscription business models, see our guide on how to analyze recurring revenue stocks.

Profitability and Margin Trends

Hims & Hers has been on a multi-year journey toward sustainable profitability, and Q2 2026 results provide the latest chapter in that story. The company reported a gross margin of [GROSS_MARGIN] for the quarter, compared to [PRIOR_YEAR_GROSS_MARGIN] in Q2 2025.

Gross margin trajectory is particularly important for Hims because it reflects the company's ability to manage the cost of fulfilling prescriptions, shipping personalized products, and maintaining its pharmacy and compounding operations. Any expansion in gross margin suggests improving operational efficiency or a favorable shift in product mix toward higher-margin offerings.

Operating Expenses and Adjusted EBITDA

On the operating expense front, total operating expenses for Q2 2026 were [TOTAL_OPEX], representing [OPEX_AS_PCT_REVENUE] of total revenue. Key line items include:

• Marketing and sales: [MARKETING_EXPENSE], or [MARKETING_PCT] of revenue, reflecting the company's ongoing customer acquisition investments
• General and administrative: [GA_EXPENSE], as the company scales its corporate infrastructure
• Research and development: [RD_EXPENSE], supporting new product development and platform enhancements

Adjusted EBITDA for the quarter was [ADJ_EBITDA], compared to [PRIOR_YEAR_ADJ_EBITDA] in Q2 2025, representing an adjusted EBITDA margin of [ADJ_EBITDA_MARGIN]. This metric is closely watched by Wall Street as a proxy for the company's underlying operating profitability before non-cash items and one-time charges.

Net Income and EPS

On a GAAP basis, Hims reported net income (loss) of [NET_INCOME] for Q2 2026, translating to earnings per share of [GAAP_EPS]. Adjusted earnings per share, which excludes stock-based compensation and other non-recurring items, came in at [ADJ_EPS] versus the consensus estimate of [CONSENSUS_EPS] (according to data compiled by Refinitiv).

Investors focused on the path to GAAP profitability should pay close attention to stock-based compensation trends, which have historically been a material gap between GAAP and non-GAAP results for high-growth companies like Hims. For context on interpreting GAAP vs. non-GAAP metrics, check out our article on understanding adjusted earnings in growth stocks.

Balance Sheet and Cash Flow Highlights

Hims & Hers ended Q2 2026 with cash, cash equivalents, and short-term investments totaling [CASH_POSITION], compared to [PRIOR_QUARTER_CASH] at the end of Q1 2026. The company's balance sheet strength is a key consideration for investors assessing the runway for continued investment in growth initiatives.

Free cash flow for the quarter was [FREE_CASH_FLOW], reflecting [FCF_TREND] compared to the year-ago period. Positive or improving free cash flow generation is an encouraging signal that the business model is beginning to fund its own growth without relying on external capital raises.

The company reported total debt of [TOTAL_DEBT], resulting in a net cash (debt) position of [NET_CASH_DEBT]. A clean balance sheet provides Hims with strategic flexibility for potential acquisitions, new product launches, or share repurchase programs.

Management Guidance and Forward Outlook

Perhaps the most market-moving element of any earnings report is forward guidance. For Q3 2026, Hims management guided for revenue in the range of [Q3_REVENUE_GUIDE_LOW] to [Q3_REVENUE_GUIDE_HIGH], compared to the prior analyst consensus of [Q3_CONSENSUS]. For the full year 2026, the company updated its revenue guidance to [FY_REVENUE_GUIDE_LOW] to [FY_REVENUE_GUIDE_HIGH].

On the profitability front, management guided for full-year adjusted EBITDA of [FY_EBITDA_GUIDE_LOW] to [FY_EBITDA_GUIDE_HIGH], which implies an adjusted EBITDA margin of approximately [IMPLIED_MARGIN_RANGE] for the remainder of the year.

Key Commentary from the Earnings Call

During the Q2 2026 earnings call, CEO Andrew Dudum and the management team addressed several topics of investor interest. Key themes from the call included:

• Regulatory landscape: Management provided commentary on the evolving regulatory environment for telehealth prescribing and compounded medications, including any updates related to FDA and state-level oversight
• GLP-1 and weight management: Updates on the company's weight loss category, including customer demand trends and competitive positioning relative to branded GLP-1 manufacturers
• Product innovation pipeline: Discussion of upcoming product launches and category expansions planned for the second half of 2026
• Marketing efficiency: Insights into customer acquisition cost (CAC) trends and the effectiveness of brand-building investments versus performance marketing

Investors should review the full earnings call transcript (available via SEC filings) for nuanced commentary that may not be captured in the press release alone.

What This Means for HIMS Investors

Hims & Hers' Q2 2026 earnings report arrives at an important inflection point for the company. The stock currently trades at a forward price-to-earnings ratio of [PE_RATIO] and a price-to-sales ratio of [PS_RATIO], reflecting the market's expectations for continued high growth.

For long-term investors, the key questions remain: Can Hims sustain its subscriber growth while expanding per-user economics? Is the path to durable GAAP profitability on track? And how resilient is the business model to regulatory headwinds, particularly in the compounded medication space?

Bull case investors will point to the company's strong brand recognition, expanding total addressable market, and improving unit economics as reasons for optimism. Bears, on the other hand, may cite regulatory uncertainty, competitive threats from both traditional healthcare providers and rival telehealth platforms, and the company's reliance on categories that could face pricing pressure.

As always, investors should consider their own risk tolerance, portfolio diversification, and investment time horizon before making decisions based on any single quarterly report. For a broader perspective on the telehealth sector, see our analysis of top telehealth stocks to watch in 2026.

Analyst Reactions and Price Target Updates

Following the Q2 2026 earnings release, several Wall Street analysts updated their ratings and price targets for HIMS stock. The consensus price target stands at [CONSENSUS_PT], with a range of [LOW_PT] to [HIGH_PT] across covering analysts (per Bloomberg data). The consensus rating is [CONSENSUS_RATING], with [BUY_COUNT] buy ratings, [HOLD_COUNT] hold ratings, and [SELL_COUNT] sell ratings.

Notable analyst commentary highlighted [ANALYST_THEMES], with particular attention paid to the company's ability to execute on its guidance and navigate the competitive landscape. Investors should keep in mind that analyst price targets represent opinions, not guarantees, and can change rapidly based on new information.